Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-03T05:39:48.277Z Has data issue: false hasContentIssue false
  • English
  • Français

Salivary clusterin as a biomarker of tobacco consumption in nicotine addicts undergoing smoking cessation therapy

Published online by Cambridge University Press:  14 April 2020

Iñigo Pallardo-Fernández ,
Victoria Iglesias ,
Carmen Rodríguez-Rivera ,
Carmen González-Martín  and
Luis F. Alguacil Open the ORCID record for Luis F. Alguacil [Opens in a new window]
Iñigo Pallardo-Fernández
Affiliation:
Translational Addiction Research Group, San Pablo CEU University, Alcorcón, Spain
Victoria Iglesias
Affiliation:
Translational Addiction Research Group, San Pablo CEU University, Alcorcón, Spain CMSc Fuencarral, Madrid Salud, Madrid, Spain
Carmen Rodríguez-Rivera
Affiliation:
Translational Addiction Research Group, San Pablo CEU University, Alcorcón, Spain
Carmen González-Martín
Affiliation:
Translational Addiction Research Group, San Pablo CEU University, Alcorcón, Spain
Luis F. Alguacil*
Affiliation:
Translational Addiction Research Group, San Pablo CEU University, Alcorcón, Spain
*
Author for correspondence: Luis F. Alguacil, E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Introduction

Recent studies have led to suggest that the multifunctional protein clusterin could be envisaged as a potential diagnostic biomarker of addictive behaviours. However, this hypothesis has not been yet tested in nicotine addicts.

Aims

We have studied possible associations between clusterin levels in saliva from smokers under cessation treatment and variables related to tobacco consumption, dependence and addiction.

Methods

Eighty-one patients were included in an ambulatory smoking cessation programme that involved the use of pharmacological and behavioural therapy. The participants underwent psychological assessment of addiction and dependence (DAST-20, ASSIST, Fagerström tests) and provided saliva samples at the onset of the intervention and 6 months after smoking discontinuation to study the evolution of clusterin levels by enzyme-linked immunosorbent assays.

Results

Clusterin concentration did not correlate with nicotine addiction/dependence scores but was significantly elevated in smokers with prolonged tobacco use and high intensity of tobacco consumption. Moreover, the levels of the protein significantly decreased 6 months after smoking cessation.

Conclusions

The results obtained provide strong evidence of a close association between tobacco use and salivary clusterin, a protein that emerges as a biomarker of tobacco toxicity with potential interest to monitor the beneficial effects of smoking cessation.

Keywords

Clusterinsmoking cessation
Type
Brief Report
Information
Journal of Smoking Cessation , Volume 15 , Issue 3 , September 2020 , pp. 171 - 174
Copyright
Copyright © The Author(s), 2020. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Becoña, E., & Vázquez, F. L. (1998). The Fagerström test for nicotine dependence in a Spanish sample. Psychological Reports, 83, 1455–1458.Google Scholar
Boggs, L. N., Fuson, K. S., Baez, M., Churgay, L., McClure, D., Becker, G., & May, P.C. (1996). Clusterin (Apo J) protects against in vitro amyloid-beta (1-40) neurotoxicity. Journal of Neurochemistry, 67, 1324–1327.CrossRefGoogle Scholar
Butelman, E. R., & Kreek, M. J. (2017). Medications for substance use disorders (SUD): Emerging approaches. Expert Opinion on Emerging Drugs, 22, 301–315.CrossRefGoogle ScholarPubMed
DiFranza, J. R., Wellman, R. J., Savageau, J. A., Beccia, A., Ursprung, W. W., & McMillen, R. (2012). What aspect of dependence does the Fagerström test for nicotine dependence measure? ISRN Addiction, 2013, 906276.Google ScholarPubMed
Huang, Z., Cheng, C., Jiang, L., Yu, Z., Cao, F., Zhong, J., … Sun, X. (2016). Intraventricular apolipoprotein ApoJ infusion acts protectively in Traumatic Brain Injury. Journal of Neurochemistry, 136, 1017–1025.CrossRefGoogle ScholarPubMed
May, P. C., Robison, P., Fuson, K., Smalstig, B., Stephenson, D., & Clemens, J. A. (1992). Sulfated glycoprotein-2 expression increases in rodent brain after transient global ischemia. Brain Research. Molecular Brain Research, 15, 33–39.CrossRefGoogle ScholarPubMed
Oberbach, A., Blüher, M., Wirth, H., Till, H., Kovacs, P., Kullnick, Y., … von Bergen, M. (2011). Metabolomic profiling of serum reveals association of the complement system with obesity and identifies novel markers of body fat mass changes. Journal of Proteome Research, 10, 4769–4788.CrossRefGoogle ScholarPubMed
Park, C. H., Kim, Y. S., Lee, H. K., Kim, Y. H., Choi, M. Y., Jung, D. E., … Cho, G.J. (2007). Citicoline reduces upregulated clusterin following kainic acid injection in the rat retina. Current Eye Research, 32, 1055–1063.CrossRefGoogle ScholarPubMed
Pérez Gálvez, B., García Fernández, L., de Vicente Manzanaro, M. P., Oliveras Valenzuela, M. A., & Lahoz Lafuente, M. (2010). Spanish Validation of the Drug Abuse Screening Test (DAST-20 and DAST-10). Health and Addictions Journal, 10, 35–50.Google Scholar
Rodríguez-Rivera, C., Pérez-García, C., Muñoz-Rodríguez, J. R., Vicente-Rodríguez, M., Polo, F., Ford, R. M., … Alguacil, L. F. (2019). Proteomic identification of biomarkers associated with eating control and bariatric surgery outcomes in patients with morbid obesity. World Journal of Surgery, 43, 744–750.CrossRefGoogle ScholarPubMed
Rubio Valldolid, G., Martínez-Raga, J., Martínez-Gras, I., Ponce Alfaro, G., de la Cruz Bértolo, J., Jurado Barba, R., … Zarco Montejo, J. (2014). Validation of the Spanish version of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). Psicothema, 26, 180–185.Google Scholar
Tomasi, D., & Volkow, N. D. (2013). Striatocortical pathway dysfunction in addiction and obesity: Differences and similarities. Critical Reviews in Biochemistry and Molecular Biology, 48, 1–19.CrossRefGoogle ScholarPubMed
Won, J. C., Park, C. Y., Oh, S. W., Lee, E. S., Youn, B. S., & Kim, M. S. (2014). Plasma clusterin (ApoJ) levels are associated with adiposity and systemic inflammation. PLoS ONE, 9, e103351.CrossRefGoogle ScholarPubMed
Zhang, Q., Zhou, W., Kundu, S., Jang, T. L., Yang, X., Pins, M., … Lee, C. (2006). The leader sequence triggers and enhances several functions of clusterin and is instrumental in the progression of human prostate cancer in vivo and in vitro. BJU International, 98, 452–460.CrossRefGoogle ScholarPubMed
Zinkie, S., Gentil, B. J., Minotti, S., & Durham, H. D. (2013). Expression of the protein chaperone, clusterin, in spinal cord cells constitutively and following cellular stress, and upregulation by treatment with Hsp90 inhibitor. Cell Stress & Chaperones, 18, 745–758.CrossRefGoogle ScholarPubMed